Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Immunology Drugs in Phase I Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              Inflazome

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              IRELAND Ireland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study

              Contact the Supplier

              Lead Product(s): Somalix

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 27, 2020

              Details:

              Results from the first-in-human study showed excellent safety, tolerability and pharmacokinetics in healthy subjects resulting in target engagment at all doses tested.

              Harbour BioMed

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody

              Contact the Supplier

              Lead Product(s): HBM9161

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 21, 2020

              Details:

              The results demonstrated an excellent safety profile and potent IgG reduction capability. The full study will be presented at an upcoming international conference.

              INmune Bio

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              INmune Bio, Inc. Awarded $500,000 Grant

              Contact the Supplier

              Lead Product(s): XPro1595

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: ALS Association

              Deal Size: $0.5 million Upfront Cash: Undisclosed

              Deal Type: Funding February 10, 2020

              Details:

              The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS).

              Xencor

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Aimmune Licenses Worldwide Rights to Xencor’s XmAb®7195

              Contact the Supplier

              Lead Product(s): XmAb7195

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Aimmune Therapeutics

              Deal Size: $395.0 million Upfront Cash: $10.0 million

              Deal Type: Licensing Agreement February 05, 2020

              Details:

              Aimmune Therapeutics has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 from Xencor, Inc.

              Jasper Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million

              Contact the Supplier

              Lead Product(s): JSP191

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Abingworth

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 09, 2020

              Details:

              Funds will be used to advance JSP191, the first clinical-stage antibody designed for use as a single and combination conditioning agent in patients undergoing curative allogeneic hematopoietic cell transplan

              Aclaris Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK...

              Contact the Supplier

              Lead Product(s): ATI-450,Methotrexate

              Therapeutic Area: Immunology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2020

              Details:

              ATI-450 resulted in inhibition of TNF?, IL1?, IL8, and IL6, was generally well-tolerated at all doses tested in the trial; had no significant food effect or drug-drug interaction with methotrexate.

              PharmaCompass__DigitalAd